Tesla
Dividend Schedule
Stock Rankings
ETF Rankings
Crypto Rankings
4.0
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, specializing in therapies designed to activate and enhance the immune system’s ability to identify and destroy disease cells.
Its research strategy centers on combining different immune-modulating technologies to generate durable immune responses in complex diseases, particularly in oncology.
Core areas of development include:
-
Cancer immunotherapies targeting solid tumors
-
Therapeutic vaccine platforms based on viral vectors
-
Allogeneic cell therapies designed to activate immune responses
-
NK cell and T-cell activation technologies
-
Immunotherapy candidates for oncology and infectious diseases
ImmunityBio’s clinical programs primarily focus on conditions such as bladder cancer, metastatic tumors, and other solid cancers, with multiple therapies undergoing different stages of clinical development.
Industry dynamics affecting the company include regulatory approval processes, clinical trial outcomes, competition in oncology immunotherapy, research and development funding, and broader healthcare policy developments.
ImmunityBio, Inc. is listed on the Nasdaq under the ticker IBRX.
History and Development
ImmunityBio was founded in 2014 in California as a biotechnology company focused on developing immunotherapy platforms for cancer treatment.
Early research programs centered on designing therapies capable of stimulating stronger immune responses against cancer cells through combinations of vaccine-based technologies and immune cell activation strategies.
A key milestone occurred in 2021, when NantKwest merged with ImmunityBio, consolidating the companies’ immunotherapy research platforms and expanding the combined organization’s clinical development pipeline.
Since then, the company has continued advancing clinical programs in oncology and infectious disease treatments, while investing in research infrastructure and manufacturing capabilities designed to support the development of next-generation immunotherapies.
Additional Information
ImmunityBio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $7.45 billion, with shareholders equity totaling $-869.13 million.
The Company is listed on the [MARKET_NAME]
Over the past 12 months, ImmunityBio Inc. reported $140.98 million in revenue, generating net income of $-854.53 million.
Key financial metrics include a P/E ratio of -8.72, a price-to-book (P/B) ratio of -8.57, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker IBRX.
